Home/Pipeline/COVID-19 STI-2020 (mAb)

COVID-19 STI-2020 (mAb)

COVID-19

Phase 2Active

Key Facts

Indication

COVID-19

Phase

Phase 2

Status

Active

Company

Sorrento Therapeutics

About Sorrento Therapeutics

Sorrento Therapeutics' mission is to apply cutting-edge science to develop innovative therapies for cancer, pain, and COVID-19. The company has historically grown through an aggressive acquisition strategy, amassing a diverse toolkit of technology platforms including a fully human antibody library, CAR-T, oncolytic viruses, and non-opioid pain delivery. Despite building an extensive pipeline, Sorrento faces severe financial distress, having filed for Chapter 11 bankruptcy in February 2023 to facilitate a strategic restructuring while attempting to advance key clinical assets.

View full company profile

Therapeutic Areas

Oncology Pain Management Infectious Disease

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
Adjuvanted Cell-Based COVID-19 Vaccine	CSL Seqirus	Marketed	Commercial (region-dependent)
Sequential Dialysis Technique	Halberd	Discovery	Conceptual / Dormant
Amubarvimab + Romlusevimab (BRII-196/BRII-198)	Brii Biosciences	Approved	Commercial (China)
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active